A phase II multicenter prospective study to evaluate the safety and efficacy of myeloablative-dose treosulfan plus fludarabine (FT14) conditioning regimen in allogeneic HSCT for AML patients aged 40-65 in first complete remission

A new transplant approach achieved low relapse rates and excellent safety, offering patients a potentially less toxic alternative to standard conditioning.

What the study was

Journal

Bone Marrow Transplant

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.